These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 23707993

  • 1. Alpha-1 adrenoceptor-angiotensin II type 1 receptor cross-talk and its relevance in clinical medicine.
    Vittorio TJ, Fudim M, Wagman G, Kosmas CE.
    Cardiol Rev; 2014; 22(2):51-5. PubMed ID: 23707993
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators.
    N Engl J Med; 2001 Dec 06; 345(23):1667-75. PubMed ID: 11759645
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA, CHARM Investigators.
    Eur J Heart Fail; 2008 Feb 06; 10(2):157-63. PubMed ID: 18242128
    [Abstract] [Full Text] [Related]

  • 5. Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure.
    Hennekens CH, Kowalczykowski M, Hollar D.
    J Cardiovasc Pharmacol Ther; 2006 Jun 06; 11(2):149-52. PubMed ID: 16891293
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators.
    Am Heart J; 2006 May 06; 151(5):985-91. PubMed ID: 16644319
    [Abstract] [Full Text] [Related]

  • 8. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 9. Exploring new treatment strategies in heart failure.
    Swedberg K.
    Blood Press Suppl; 2000 Oct 20; 1():44-8. PubMed ID: 11059637
    [Abstract] [Full Text] [Related]

  • 10. [Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study].
    Piérard L.
    Rev Med Liege; 2002 Jan 20; 57(1):57-9. PubMed ID: 11899501
    [Abstract] [Full Text] [Related]

  • 11. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker).
    Dimopoulos K, Salukhe TV, Coats AJ, Mayet J, Piepoli M, Francis DP.
    Int J Cardiol; 2004 Feb 20; 93(2-3):105-11. PubMed ID: 14975535
    [Abstract] [Full Text] [Related]

  • 12. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
    Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN, Val-HeFT Investigators (Valsartan Heart Failure Trial).
    J Am Coll Cardiol; 2002 Oct 16; 40(8):1414-21. PubMed ID: 12392830
    [Abstract] [Full Text] [Related]

  • 13. Effects of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on beta-adrenoceptor signaling in heart failure produced by myocardial Infarction in rabbits: reversal of altered expression of beta-adrenoceptor kinase and G i alpha.
    Makino T, Hattori Y, Matsuda N, Onozuka H, Sakuma I, Kitabatake A.
    J Pharmacol Exp Ther; 2003 Jan 16; 304(1):370-9. PubMed ID: 12490614
    [Abstract] [Full Text] [Related]

  • 14. [CHARM study--new strategy for the treatment of heart failure].
    Hasegawa H, Komuro I.
    Nihon Rinsho; 2004 May 16; 62(5):995-1002. PubMed ID: 15148833
    [Abstract] [Full Text] [Related]

  • 15. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.
    Tsuyuki RT, Yusuf S, Rouleau JL, Maggioni AP, McKelvie RS, Wiecek EM, Wang Y, Pogue J, Teo KK, White M, Avezum A, Latini R, Held P, Lindgren E, Probstfield J.
    Can J Cardiol; 1997 Dec 16; 13(12):1166-74. PubMed ID: 9444298
    [Abstract] [Full Text] [Related]

  • 16. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
    Jneid H, Moukarbel GV, Dawson B, Hajjar RJ, Francis GS.
    Am J Med; 2007 Dec 16; 120(12):1090.e1-8. PubMed ID: 18060931
    [Abstract] [Full Text] [Related]

  • 17. [Drug treatment for chronic heart failure with reduced ejection fraction].
    Rickenbacher P.
    Ther Umsch; 2011 Feb 16; 68(2):71-9. PubMed ID: 21271537
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB.
    J Hypertens Suppl; 2006 Mar 16; 24(1):S3-7. PubMed ID: 16601570
    [Abstract] [Full Text] [Related]

  • 19. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun 16; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 20. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].
    Skvortsov AA, Mareev VIu, Nasonova SN, Sychev AV, Arbolishvili GN, Baklanova NA, Masenko VP, Belenkov IuN.
    Ter Arkh; 2006 Jun 16; 78(9):61-71. PubMed ID: 17076227
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.